Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

Key finding

Method / model

Relevance

Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet, 402(10401), 529-544.